Literature DB >> 19890749

[GA2LEN (Global Allergy and Asthma European Network), the perspective of the German speaking centers].

Stefan Wöhrl1, Katja Radon, Johannes Ring, Katharina Moritz, Cezmi Akdis, Peter Burney, Paul Van Cauwenberge, Jean Bousquet, Torsten Zuberbier.   

Abstract

Allergic diseases represent a major health problem in Europe. They are increasing in prevalence, severity and costs. GA2LEN (Global Allergy and Asthma European Network), an FP6 Network of Excellence, was created in 2005 as a vehicle to ensure excellence in research bringing together research and clinical institutions to combat fragmentation in the European research area and to tackle allergy as a whole. GA2LEN benefited greatly from the voluntary efforts of researchers who are strongly committed to this model of pan-European collaboration. The network was organized in order to increase networking for scientific projects in allergy and asthma around Europe and to make GA2LEN the world leader in the field. Besides these activities, research has been jointly made and the first papers are being published. GA2LEN achievements in general can be grouped as those for a durable infrastructure built up during the project phase those which are project-related work based on these novel infrastructures, and the development and implementations of guidelines. The major achievements of GA2LEN are reported in this paper.

Entities:  

Mesh:

Year:  2009        PMID: 19890749     DOI: 10.1007/s00508-009-1246-z

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  64 in total

Review 1.  EAACI/GA2LEN/EDF guideline: management of urticaria.

Authors:  T Zuberbier; C Bindslev-Jensen; W Canonica; C E H Grattan; M W Greaves; B M Henz; A Kapp; M M A Kozel; M Maurer; H F Merk; T Schäfer; D Simon; G A Vena; B Wedi
Journal:  Allergy       Date:  2006-03       Impact factor: 13.146

2.  Occupation and adult onset of rhinitis in the general population.

Authors:  K Radon; U Gerhardinger; A Schulze; J-P Zock; D Norback; K Toren; D Jarvis; L Held; J Heinrich; B Leynaert; D Nowak; M Kogevinas
Journal:  Occup Environ Med       Date:  2007-07-30       Impact factor: 4.402

3.  Estimation of outdoor NO(x), NO(2), and BTEX exposure in a cohort of pregnant women using land use regression modeling.

Authors:  Inmaculada Aguilera; Jordi Sunyer; Rosalía Fernández-Patier; Gerard Hoek; Amelia Aguirre-Alfaro; Kees Meliefste; M Teresa Bomboi-Mingarro; Mark J Nieuwenhuijsen; Dolores Herce-Garraleta; Bert Brunekreef
Journal:  Environ Sci Technol       Date:  2008-02-01       Impact factor: 9.028

4.  Rhinitis and onset of asthma: a longitudinal population-based study.

Authors:  Rafea Shaaban; Mahmoud Zureik; David Soussan; Catherine Neukirch; Joachim Heinrich; Jordi Sunyer; Matthias Wjst; Isa Cerveri; Isabelle Pin; Jean Bousquet; Deborah Jarvis; Peter G Burney; Françoise Neukirch; Bénédicte Leynaert
Journal:  Lancet       Date:  2008-09-20       Impact factor: 79.321

Review 5.  Rhinitis and asthma in athletes: an ARIA document in collaboration with GA2LEN.

Authors:  S Bonini; M Bonini; J Bousquet; V Brusasco; G W Canonica; K-H Carlsen; L Corbetta; J Cummiskey; L Delgado; S R Del Giacco; T Haahtela; S Jaeger; C Moretti; P Palange; G Passalacqua; D Passali; B K Pedersen; T Popov; G Rasi; M T Ventura; A M Vignola
Journal:  Allergy       Date:  2006-06       Impact factor: 13.146

6.  Severity and impairment of allergic rhinitis in patients consulting in primary care.

Authors:  Jean Bousquet; Françoise Neukirch; Philippe J Bousquet; Pierre Gehano; Jean Michel Klossek; Martine Le Gal; Bashar Allaf
Journal:  J Allergy Clin Immunol       Date:  2005-12-02       Impact factor: 10.793

7.  Efficacy of desloratadine in intermittent allergic rhinitis: a GA(2)LEN study.

Authors:  J Bousquet; C Bachert; G W Canonica; J Mullol; P Van Cauwenberge; C Bindslev Jensen; W J Fokkens; J Ring; P Keith; R Lorber; T Zuberbier
Journal:  Allergy       Date:  2009-07-14       Impact factor: 13.146

8.  A case-control study of the relation between plasma selenium and asthma in European populations: a GAL2EN project.

Authors:  P Burney; J Potts; J Makowska; M Kowalski; J Phillips; L Gnatiuc; S Shaheen; G Joos; P Van Cauwenberge; T van Zele; K Verbruggen; Y van Durme; I Derudder; S Wohrl; J Godnic-Cvar; B Salameh; L Skadhauge; G Thomsen; T Zuberbier; K C Bergmann; L Heinzerling; H Renz; N Al-Fakhri; B Kosche; A Hildenberg; N G Papadopoulos; P Xepapadaki; K Zannikos; M Gjomarkaj; A Bruno; E Pace; S Bonini; M Bresciani; C Gramiccioni; W Fokkens; E J M Weersink; K-H Carlsen; E Bakkeheim; C Loureiro; C M Villanueva; C Sanjuas; J-P Zock; B Lundback; C Janson
Journal:  Allergy       Date:  2008-07       Impact factor: 13.146

9.  Non-invasive markers of airway inflammation and remodeling in childhood asthma.

Authors:  Rosalia Gagliardo; Stefania La Grutta; Pascal Chanez; Mirella Profita; Alessandra Paternò; Fabio Cibella; Jean Bousquet; Giovanni Viegi; Mark Gjomarkaj
Journal:  Pediatr Allergy Immunol       Date:  2009-09-25       Impact factor: 6.377

Review 10.  The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine.

Authors:  J Bousquet; C Bindslev-Jensen; G W Canonica; W Fokkens; H Kim; M Kowalski; A Magnan; J Mullol; P van Cauwenberge
Journal:  Allergy       Date:  2004       Impact factor: 13.146

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.